SGAM
DNLI icon

Smith Group Asset Management’s Denali Therapeutics DNLI Stock Holding History

Smith Group Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-110
Closed -$5K – 300
2021
Q4 		$5K Hold
110
– – ﹤0.01% 341
2021
Q3 		$6K Buy
+110
New +$6.2K ﹤0.01% 341

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Smith Group Asset Management's DNLI Position: Q1 2022 in Review

Smith Group Asset Management sold out of Denali Therapeutics (DNLI) in Q1 2022, closing a stake of 110 shares — an estimated $5K sold.

Smith Group Asset Management first reported a position in DNLI in Q3 2021 and held it in 2 quarters. The position peaked at $6K in Q3 2021. 190 funds tracked by Wall St. Rank hold DNLI as of Q1 2022.

  • Smith Group Asset Management reported no remaining Denali Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Smith Group Asset Management sold 110 Denali Therapeutics shares in Q1 2022, an estimated $5K.
  • Smith Group Asset Management first reported a position in Denali Therapeutics in Q3 2021 and held it in 2 quarters.
  • Smith Group Asset Management's Denali Therapeutics position peaked at $6K in Q3 2021.
  • 190 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2022.

Based on Smith Group Asset Management's 13F filing for Q1 2022, filed 5 May 2022.